Welcome to our dedicated page for Aclarion SEC filings (Ticker: ACON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spine-care innovators like Aclarion pack their filings with clinical-trial data, FDA milestones, and complex revenue notes. Locating R&D spend or spotting Aclarion insider trading Form 4 transactions across hundreds of pages is challenging. Whether you are tracking an Aclarion quarterly earnings report 10-Q filing or monitoring Aclarion Form 4 insider transactions real-time, raw EDGAR documents rarely answer questions quickly.
Stock Titan solves that problem. Our AI reads every submission the moment it appears on EDGAR, turning dense language into clear takeaways. Need “Aclarion SEC filings explained simply” or a fast Aclarion earnings report filing analysis? One click delivers an executive summary, key numbers, and risk-factor highlights. Filters surface 10-K, 10-Q, 8-K, and proxy data, while real-time alerts flag Aclarion executive stock transactions Form 4 so you never miss insider buying before pivotal clinical updates.
Dig deeper into what matters for this company: an Aclarion annual report 10-K simplified outlines Nociscan’s SaaS revenue trajectory, patent counts, and reimbursement assumptions; 8-Ks keep you current on imaging-center contracts and trial readouts—exactly why users search for “Aclarion 8-K material events explained.” The proxy statement reveals board incentives—look for “Aclarion proxy statement executive compensation” to gauge alignment. From clinical progress checkpoints to segment margin shifts, Stock Titan’s AI-powered summaries, real-time alerts, and complete form coverage turn every ACON filing into actionable insight without the steep learning curve of understanding Aclarion SEC documents with AI.
Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering, selling 64,000 shares of common stock at $8.36 per share and issuing pre-funded warrants to purchase up to 236,000 shares. The company expects approximately $2.5 million in gross proceeds, with closing anticipated on or about October 14, 2025, subject to customary conditions.
The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 and include a beneficial ownership cap of 4.99% or 9.99%, adjustable with 61 days’ prior notice. Dawson James Securities is the exclusive placement agent and will receive a 7.0% cash fee on gross proceeds plus expense reimbursement. Aclarion plans to use net proceeds to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support, and other general corporate purposes.
Aclarion, Inc. launched a primary offering of 64,000 shares of common stock and pre-funded warrants for up to 236,000 shares under a Rule 424(b)(5) prospectus supplement. The shares are priced at $8.36 and the pre-funded warrants at $8.35999 each, with a nominal exercise price of $0.00001. The pre-funded warrants do not expire and are exercisable immediately, subject to a 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership cap.
Gross proceeds are $2,507,997.64. After a 7.0% placement fee payable to Dawson James Securities ($175,559.83), proceeds to the company before expenses are $2,332,437.81, with net proceeds estimated at approximately $2.2 million. The company plans to use the funds for market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support.
Common stock trades on Nasdaq as ACON; the pre-funded warrants will not be listed. Shares outstanding were 582,371 as of June 30, 2025, and would be 882,371 assuming full cash exercise of the pre-funded warrants. Dawson James acted on a reasonable best efforts basis, with delivery expected on or about October 14, 2025.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
